Instil Bio, Inc. Earnings Per Share (Basic)
Instil Bio, Inc. (TIL) reported Earnings Per Share (Basic) of -$0.63 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-13
- Instil Bio, Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$0.63.
- Instil Bio, Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$0.62.
- Instil Bio, Inc. earnings per share, basic for the quarter ending 2025-12-31 was -$1.21.
- Instil Bio, Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$2.01.
- Instil Bio, Inc. earnings per share, basic for fiscal 2025 was -$10.70.
- Instil Bio, Inc. earnings per share, basic for fiscal 2024 was -$11.39.
- Instil Bio, Inc. earnings per share, basic for fiscal 2023 was -$24.00.
- Instil Bio, Inc. earnings per share, basic for fiscal 2022 was -$34.46.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 6 month as first filed | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 9 month as first filed | Earnings Per Share, Basic 12 month | Earnings Per Share, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$0.63 10-Q · filed 2026-08-13 | -$1.25 10-Q · filed 2026-08-13 | -$2.46 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$4.47 derived: net income ÷ weighted average shares · filed 2026-08-13 | ||||
| 2026-03-31 | -$0.62 10-Q · filed 2026-05-15 | -$1.83 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$3.84 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$7.04 derived: net income ÷ weighted average shares · filed 2026-08-13 | ||||
| 2025-12-31 | -$1.21 derived: net income ÷ weighted average shares · filed 2026-03-27 | -$3.22 derived: net income ÷ weighted average shares · filed 2026-03-27 | -$6.43 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$10.70 10-K · filed 2026-03-27 | ||||
| 2025-09-30 | -$2.01 10-Q · filed 2025-11-13 | -$5.24 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$9.53 10-Q · filed 2025-11-13 | -$11.37 derived: net income ÷ weighted average shares · filed 2026-08-13 | ||||
| 2025-06-30 | -$3.24 10-Q · filed 2026-08-13 | -$7.55 10-Q · filed 2026-08-13 | -$9.38 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$12.92 derived: net income ÷ weighted average shares · filed 2026-08-13 | ||||
| 2025-03-31 | -$4.32 10-Q · filed 2026-05-15 | -$6.14 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$9.68 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$11.97 derived: net income ÷ weighted average shares · filed 2026-08-13 | ||||
| 2024-12-31 | -$1.82 derived: net income ÷ weighted average shares · filed 2026-03-27 | -$5.36 derived: net income ÷ weighted average shares · filed 2026-03-27 | -$7.65 derived: net income ÷ weighted average shares · filed 2026-03-27 | -$11.39 10-K · filed 2026-03-27 | ||||
| 2024-09-30 | -$3.54 10-Q · filed 2025-11-13 | -$5.83 derived: net income ÷ weighted average shares · filed 2025-11-13 | -$9.57 10-Q · filed 2025-11-13 | -$11.56 derived: net income ÷ weighted average shares · filed 2025-11-13 | ||||
| 2024-06-30 | -$2.29 10-Q · filed 2025-08-13 | -$6.03 10-Q · filed 2025-08-13 | -$8.02 derived: net income ÷ weighted average shares · filed 2025-11-13 | -$18.39 derived: net income ÷ weighted average shares · filed 2025-11-13 | ||||
| 2024-03-31 | -$3.74 10-Q · filed 2025-05-13 | -$5.72 derived: net income ÷ weighted average shares · filed 2025-11-13 | -$16.09 derived: net income ÷ weighted average shares · filed 2025-11-13 | -$18.96 derived: net income ÷ weighted average shares · filed 2025-11-13 | ||||
| 2023-12-31 | -$1.99 derived: net income ÷ weighted average shares · filed 2025-03-04 | -$12.36 derived: net income ÷ weighted average shares · filed 2025-03-04 | -$15.22 derived: net income ÷ weighted average shares · filed 2025-03-04 | -$24.00 10-K · filed 2025-03-04 | ||||
| 2023-09-30 | -$10.37 10-Q · filed 2024-11-13 | -$0.52 10-Q · filed 2023-11-13 | -$13.24 derived: net income ÷ weighted average shares · filed 2024-11-13 | -$22.01 10-Q · filed 2024-11-13 | -$1.10 10-Q · filed 2023-11-13 | $2.30 derived: net income ÷ weighted average shares · filed 2024-11-13 | ||
| 2023-06-30 | -$2.87 10-Q · filed 2024-08-13 | -$0.14 10-Q · filed 2023-08-14 | -$11.64 10-Q · filed 2024-08-13 | -$0.58 10-Q · filed 2023-08-14 | $1.11 derived: net income ÷ weighted average shares · filed 2024-11-13 | $3.38 derived: net income ÷ weighted average shares · filed 2024-11-13 | ||
| 2023-03-31 | -$8.77 10-Q · filed 2024-05-10 | -$0.44 10-Q · filed 2023-05-11 | $0.62 derived: net income ÷ weighted average shares · filed 2024-11-13 | $2.22 derived: net income ÷ weighted average shares · filed 2024-11-13 | $9.35 derived: net income ÷ weighted average shares · filed 2024-11-13 | |||
| 2022-12-31 | $0.15 derived: net income ÷ weighted average shares · filed 2024-03-21 | $0.95 derived: net income ÷ weighted average shares · filed 2024-03-21 | $4.91 derived: net income ÷ weighted average shares · filed 2024-03-21 | -$34.46 10-K · filed 2024-03-21 | -$1.72 10-K · filed 2023-03-31 | |||
| 2022-09-30 | -$0.43 10-Q · filed 2023-11-13 | -$0.89 derived: net income ÷ weighted average shares · filed 2023-11-13 | -$1.31 10-Q · filed 2023-11-13 | -$1.74 derived: net income ÷ weighted average shares · filed 2023-11-13 | ||||
| 2022-06-30 | -$0.46 10-Q · filed 2023-08-14 | -$0.88 10-Q · filed 2023-08-14 | -$1.30 derived: net income ÷ weighted average shares · filed 2023-11-13 | -$1.64 derived: net income ÷ weighted average shares · filed 2023-11-13 | ||||
| 2022-03-31 | -$0.42 10-Q · filed 2023-05-11 | -$0.85 derived: net income ÷ weighted average shares · filed 2023-11-13 | -$1.18 derived: net income ÷ weighted average shares · filed 2023-11-13 | -$1.46 derived: net income ÷ weighted average shares · filed 2023-11-13 | ||||
| 2021-12-31 | -$0.43 derived: net income ÷ weighted average shares · filed 2023-03-31 | -$0.76 derived: net income ÷ weighted average shares · filed 2023-03-31 | -$1.04 derived: net income ÷ weighted average shares · filed 2023-03-31 | -$1.48 10-K · filed 2023-03-31 | ||||
| 2021-09-30 | -$0.33 10-Q · filed 2022-11-14 | -$0.61 derived: net income ÷ weighted average shares · filed 2022-11-14 | -$1.03 10-Q · filed 2022-11-14 | -$1.53 derived: net income ÷ weighted average shares · filed 2022-11-14 | ||||
| 2021-06-30 | -$0.27 10-Q · filed 2022-08-12 | -$0.71 10-Q · filed 2022-08-12 | -$1.25 derived: net income ÷ weighted average shares · filed 2022-11-14 | -$1.68 derived: net income ÷ weighted average shares · filed 2022-11-14 | ||||
| 2021-03-31 | -$0.66 10-Q · filed 2022-05-16 | -$1.55 derived: net income ÷ weighted average shares · filed 2022-11-14 | -$2.07 derived: net income ÷ weighted average shares · filed 2022-11-14 | -$2.64 derived: net income ÷ weighted average shares · filed 2022-11-14 | ||||
| 2020-12-31 | -$1.00 derived: net income ÷ weighted average shares · filed 2022-03-07 | -$1.44 derived: net income ÷ weighted average shares · filed 2022-03-07 | -$1.98 derived: net income ÷ weighted average shares · filed 2022-03-07 | -$2.36 10-K · filed 2022-03-07 | ||||
| 2020-09-30 | -$0.43 10-Q · filed 2021-11-15 | -$0.97 derived: net income ÷ weighted average shares · filed 2021-11-15 | -$1.32 10-Q · filed 2021-11-15 | |||||
| 2020-06-30 | -$0.55 10-Q · filed 2021-08-12 | -$0.89 10-Q · filed 2021-08-12 | ||||||
| 2020-03-31 | -$0.31 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |